Efficacy and Safety of Olmesartan Medoxomil in Patients with Stage 1 Hypertension: Blood Pressure Lowering and Goal Achievement

References

• . Lloyd-Jones D, Adams R, Carnethon M, ; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics–2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009; 119(3):480–486
   PubMed Web of Science ®Google Scholar
• . Chobanian AV, Bakris GL, Black HR, ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42(6):1206–1252
   PubMed Web of Science ®Google Scholar
• . Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–1913
   PubMed Web of Science ®Google Scholar
• . Rosendorff C. Hypertension and coronary artery disease: a summary of the American Heart Association scientific statement. J Clin Hypertens (Greenwich). 2007;9(10):790–795
   PubMedGoogle Scholar
• . Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension. 2007;49(1):69–75
   PubMed Web of Science ®Google Scholar
• . Basile J, Neutel J. Overcoming clinical inertia to achieve blood pressure goals: the role of fixed-dose combination therapy. Ther Adv Cardiovasc Dis. 2010;4(2):119–127
   PubMedGoogle Scholar
• . Andrade SE, Gurwitz JH, Field TS, . Hypertension management: the care gap between clinical guidelines and clinical practice. Am J Manag Care. 2004;10(7 pt 2):481–486
   PubMed Web of Science ®Google Scholar
• . Asmar R. Targeting effective blood pressure control with angiotensin receptor blockers. Int J Clin Pract. 2006;60(3):315–320
   PubMed Web of Science ®Google Scholar
• . Brunner HR, Stumpe KO, Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Investig. 2003;23(7):419–430
   PubMed Web of Science ®Google Scholar
• . Giles TD, Oparil S, Silfani TN, Wang A, Walker JF. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. J Clin Hypertens (Greenwich). 2007;9(3):187–195
   PubMedGoogle Scholar
• . Greathouse M. Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension. Vasc Health Risk Manag. 2006;2(4):401–409
   PubMedGoogle Scholar
• . Chrysant SG, Weber MA, Wang AC, Hinman DJ. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens. 2004;17(3):252–259
   PubMed Web of Science ®Google Scholar
• . Arauz-Pacheco C, Parrott MA, Raskin P. Hypertension management in adults with diabetes. Diabetes Care. 2004;27( suppl 1):S65–S67
   Google Scholar
• . Neutel JM, Smith DH, Silfani TN, Lee Y, Weber MA. Effects of a structured treatment algorithm on blood pressure goal rates in both stage 1 and stage 2 hypertension. J Hum Hypertens. 2006;20(4):255–262
   PubMed Web of Science ®Google Scholar
• . Oparil S, Chrysant SG, Kereiakes D, . Results of an olmesartan medoxomil-based treatment regimen in hypertensive patients. J Clin Hypertens (Greenwich). 2008;10(12):911–921
   PubMed Web of Science ®Google Scholar
• . Neutel JM, Kereiakes DJ, Waverczak WF, Stoakes KA, Xu J, Shojaee A. Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes. Curr Med Res Opin. 2010;26(3):721–728
   PubMed Web of Science ®Google Scholar
• . Neutel JM, Kereiakes DJ; BENIFICIARY Investigators. An olmesartan medoxomil-based treatment algorithm is effective in achieving 24-hour blood pressure control in patients with type 2 diabetes, regardless of age, race, gender, or severity of hypertension: subgroup analysis of the BENIFICIARY study. Am J Cardiovasc Drugs. 2010; 10(5):289–303
   PubMed Web of Science ®Google Scholar
• . Kereiakes DJ, Neutel J, Stoakes KA, . The effects of an olmesartan medoxomil-based treatment algorithm on 24-hour blood pressure levels in elderly patients aged 65 and older. J Clin Hypertens (Greenwich). 2009;11(8):411–421
   PubMed Web of Science ®Google Scholar
• . Neutel JM, Cheung D, Stoakes KA, . Efficacy of olmesartan medoxomil (OM) and hydrochlorothiazide (HCTZ) in elderly (≥ 65 years) patients (pts) based on baseline (BL) hypertension (HTN) stage 1 and 2. Presented at: Annual Congress of the American Society of Hypertension (ASH); New Orleans, LA; December 5–8, 2009
   Google Scholar
• . Chrysant SG, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther. 2008;30(4):587–604
   PubMed Web of Science ®Google Scholar
• . Oparil S, Lee J, Karki S, Melino M. Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: evaluation by baseline hypertension stage and prior antihypertensive medication use. J Cardiovasc Pharmacol. 2009;54(5):427–436
   PubMed Web of Science ®Google Scholar
• . ACCORD Study Group; Cushman WC, Evans GW, Byington RP, . Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575–1585
   PubMed Web of Science ®Google Scholar
• . Mancia G, Laurent S, Agabiti-Rosei E, ; European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009; 27(11):2121–2158
   PubMed Web of Science ®Google Scholar
• . Cushman WC, Basile J. Achieving blood pressure goals: why aren't we? J Clin Hypertens (Greenwich). 2006;8(12):865–872
   PubMedGoogle Scholar
• . Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ. 1999;160(1):41–46
   PubMed Web of Science ®Google Scholar
• . Mancia G, Seravalle G, Grassi G. Tolerability and treatment compliance with angiotensin II receptor antagonists. Am J Hypertens. 2003;16(12):1066–1073
   PubMed Web of Science ®Google Scholar
• . Volpe M, Ruilope LM, McInnes GT, Waeber B, Weber MA. Angiotensin-II receptor blockers: benefits beyond blood pressure reduction? J Hum Hypertens. 2005;19(5):331–339
   PubMed Web of Science ®Google Scholar
• . Elliott WJ, Plauschinat CA, Skrepnek GH, Gause D. Persistence, adherence, and risk of discontinuation associated with commonly prescribed antihypertensive drug monotherapies. J Am Board Fam Med. 2007;20(1):72–80
   PubMed Web of Science ®Google Scholar
• . Punzi HA. Efficacy and safety of olmesartan medoxomil alone and in combination with hydrochlorothiazide. Expert Rev Cardiovasc Ther. 2009;7(3):229–239
   PubMedGoogle Scholar
• . Quan A, Chavanu K, Merkel J. A review of the efficacy of fixed-dose combinations olmesartan medoxomil/hydrochlorothiazide and amlodipine besylate/benazepril in factorial design studies. Am J Cardiovasc Drugs. 2006;6(2):103–113
   PubMedGoogle Scholar
• . Mancia G, De Backer G, Dominiczak A, ; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007; 25(6):1105–1187
   PubMed Web of Science ®Google Scholar
• . Neutel JM, Smith DH, Weber MA, Wang AC, Masonson HN. Use of an olmesartan medoxomil-based treatment algorithm for hypertension control. J Clin Hypertens (Greenwich). 2004;6(4):168–174
   PubMedGoogle Scholar
• . Chrysant SG. Safety and tolerability of an olmesartan medoxomil-based regimen in patients with stage 1 hypertension: a randomized, double-blind, placebo-controlled study. Clin Drug Investig. 2010;30(7):473–482
   PubMed Web of Science ®Google Scholar